AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease

[1]  D. Lockhart,et al.  Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  O. Shirihai,et al.  Modulation of mTOR signaling as a strategy for the treatment of Pompe disease , 2017, EMBO molecular medicine.

[3]  A. Ballabio,et al.  Transcription Factor EB Controls Metabolic Flexibility during Exercise , 2017, Cell metabolism.

[4]  A. Amalfitano,et al.  Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus , 2016, Gene Therapy.

[5]  Songtao Li,et al.  Salmeterol enhances the cardiac response to gene therapy in Pompe disease. , 2016, Molecular genetics and metabolism.

[6]  A. Broomfield,et al.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders , 2016, Journal of Inherited Metabolic Disease.

[7]  A. Ballabio,et al.  Drosophila Mitf regulates the V-ATPase and the lysosomal-autophagic pathway , 2016, Autophagy.

[8]  D. Koeberl,et al.  Preclinical Development of New Therapy for Glycogen Storage Diseases. , 2015, Current gene therapy.

[9]  G. Andria,et al.  Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J. Chan,et al.  Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  M. Kruijshaar,et al.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease , 2015, Journal of Inherited Metabolic Disease.

[12]  Carmine Mollica,et al.  A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  P. Kishnani,et al.  New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. , 2014, Pediatric endocrinology reviews : PER.

[14]  G. Gao,et al.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue , 2014, Expert opinion on drug delivery.

[15]  A. Auricchio,et al.  AAV2/8 vectors purified from culture medium with a simple and rapid protocol transduce murine liver, muscle, and retina efficiently. , 2013, Human gene therapy methods.

[16]  Katarina Kågedal,et al.  The lysosome: from waste bag to potential therapeutic target. , 2013, Journal of molecular cell biology.

[17]  Nina Raben,et al.  Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease , 2013, EMBO molecular medicine.

[18]  T. Conlon,et al.  Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.

[19]  R. Scheule,et al.  Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease , 2013, PloS one.

[20]  B. Byrne,et al.  Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice* , 2012, The Journal of Biological Chemistry.

[21]  W. Henley,et al.  The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. , 2012, Health technology assessment.

[22]  W. Hop,et al.  Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study , 2012, Orphanet Journal of Rare Diseases.

[23]  Roberto Zoncu,et al.  Amino acids and mTORC1: from lysosomes to disease. , 2012, Trends in molecular medicine.

[24]  C. Angelini,et al.  Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients , 2012, Autophagy.

[25]  C. Angelini,et al.  The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII) , 2012, Cell Death and Differentiation.

[26]  C. Phornphutkul,et al.  The emerging phenotype of long-term survivors with infantile Pompe disease , 2012, Genetics in Medicine.

[27]  Sangeeta Khare,et al.  Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .

[28]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[29]  A. Ballabio,et al.  A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB , 2012, The EMBO journal.

[30]  P. Kishnani,et al.  Infantile Pompe disease on ERT—Update on clinical presentation, musculoskeletal management, and exercise considerations , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[31]  E. Ralston,et al.  Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[32]  Roberto Zoncu,et al.  mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase , 2011, Science.

[33]  A. Ballabio,et al.  Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance , 2011, Developmental cell.

[34]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[35]  M. Lotze,et al.  The Beclin 1 network regulates autophagy and apoptosis , 2011, Cell Death and Differentiation.

[36]  J. Kornegay,et al.  Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  M. Willart,et al.  Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. , 2010, Blood.

[38]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[39]  G. Meroni,et al.  Lack of Mid1, the Mouse Ortholog of the Opitz Syndrome Gene, Causes Abnormal Development of the Anterior Cerebellar Vermis , 2010, The Journal of Neuroscience.

[40]  R. Mattaliano,et al.  Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  A. Reuser,et al.  Pompe's disease , 2008, The Lancet.

[42]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  B. Byrne,et al.  Recombinant human acid α-glucosidase , 2007, Neurology.

[44]  E. Ralston,et al.  Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  B. Thurberg,et al.  Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease , 2006, Laboratory Investigation.

[46]  B. Thurberg,et al.  High-resolution Light Microscopy (HRLM) and Digital Analysis of Pompe Disease Pathology , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  W. Hop,et al.  Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk , 2004 .

[48]  A. Vulto,et al.  Recombinant human α-glucosidase from rabbit milk in Pompe patients , 2000, The Lancet.

[49]  W. Mooi,et al.  Pathological features of glycogen storage disease type II highlighted in the knockout mouse model , 1999, The Journal of pathology.

[50]  N. Raben,et al.  Targeted Disruption of the Acid α-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II* , 1998, The Journal of Biological Chemistry.

[51]  J. Dormans,et al.  Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease) , 1985, Journal of Inherited Metabolic Disease.

[52]  B. Byrne,et al.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. , 2016, Human gene therapy.

[53]  N. Karabul,et al.  Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. , 2015, JIMD reports.

[54]  M. Kruijshaar,et al.  Ten Years of the International Pompe Survey: Patient-Reported Outcomes as a Reliable Tool for Studying Treated and Untreated Children and Adults with Non-Classic Pompe Disease. , 2015, Journal of neuromuscular diseases.

[55]  D. Sabatini,et al.  Amino acids and mTORC 1 : from lysosomes to disease , 2012 .

[56]  N. Raben,et al.  Autophagy in skeletal muscle: implications for Pompe disease. , 2009, International journal of clinical pharmacology and therapeutics.

[57]  F. Glocker,et al.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial , 2009, Journal of Neurology.

[58]  R. Mattaliano,et al.  Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  B. Byrne,et al.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.

[60]  D. Koeberl,et al.  Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  W. Hop,et al.  Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. , 2004, Pediatrics.

[62]  A. Reuser,et al.  Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. , 2000, Lancet.

[63]  J. Melvin.  Pompe's disease. , 2000, Archives of neurology.

[64]  R. Chandra.  Lysosomes in disease. , 1967, Indian journal of pediatrics.